

## Atopic Dermatitis Overview

Resource	Address
Du Toit G, et al. Food Allergy: Update on Prevention and Tolerance. <i>J Allergy Clin Immunol.</i> 2018;141:30-40.	<a href="https://www.jacionline.org/article/S0091-6749(17)31815-8/fulltext">https://www.jacionline.org/article/S0091-6749(17)31815-8/fulltext</a>
Drucker AM, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. <i>J Invest Dermatol.</i> 2017;137:26-30.	<a href="https://www.jidonline.org/article/S0022-202X(16)32120-0/fulltext">https://www.jidonline.org/article/S0022-202X(16)32120-0/fulltext</a>
Frischmeyer-Guerrero PA, et al. IgE Testing Can Predict Food Allergy Status in Patients With Moderate to Severe Atopic Dermatitis. <i>Ann Allergy Asthma Immunol.</i> 2019;122:393-400.e2.	<a href="https://www.annallergy.org/article/S1081-1206(19)30001-8/fulltext">https://www.annallergy.org/article/S1081-1206(19)30001-8/fulltext</a>
Gaudinski MR, Milner JD. Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency. <i>Immunol Allergy Clin North Am.</i> 2017;37:1-10.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S0889856116300790">https://www.sciencedirect.com/science/article/abs/pii/S0889856116300790</a>
Guttman-Yassky E, et al. Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis With Implications for Treatment. <i>Exp Dermatol.</i> 2018;27:409-417.	<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/exd.13336">https://onlinelibrary.wiley.com/doi/full/10.1111/exd.13336</a>
Kantor R, Silverberg JI. Environmental Risk Factors and Their Role in the Management of Atopic Dermatitis. <i>Expert Rev Clin Immunol.</i> 2017;13:15-26.	<a href="https://www.tandfonline.com/doi/full/10.1080/1744666X.2016.1212660">https://www.tandfonline.com/doi/full/10.1080/1744666X.2016.1212660</a>
Kim K. Influences of Environmental Chemicals on Atopic Dermatitis. <i>Toxicol Res.</i> 2015;31:89-96.	<a href="http://koreascience.or.kr/article/JAKO201520448048501.page">http://koreascience.or.kr/article/JAKO201520448048501.page</a>
Manea I, et al. Overview of Food Allergy Diagnosis. <i>Clujul Med.</i> 2016;89:5-10.	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777468/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777468/</a>
McLean WHI. Filaggrin Failure - From Ichthyosis Vulgaris to Atopic Eczema and Beyond. <i>Br J Dermatol.</i> 2016;175(suppl 2):4-7.	<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14997">https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14997</a>
Napolitano M, et al. Adult Atopic Dermatitis: A Review. <i>G Ital Dermatol Venereol.</i> 2016;151:403-411.	<a href="https://www.minervamedica.it/en/journals/dermatologia-venereologia/article.php?cod=R23Y2016N04A0403">https://www.minervamedica.it/en/journals/dermatologia-venereologia/article.php?cod=R23Y2016N04A0403</a>
Owen JL, et al. The Role and Diagnosis of Allergic Contact Dermatitis in Patients With Atopic Dermatitis. <i>Am J Clin Dermatol.</i> 2018;19:293-302.	<a href="https://link.springer.com/article/10.1007/s40257-017-0340-7">https://link.springer.com/article/10.1007/s40257-017-0340-7</a>
Paller AS, et al. The Microbiome in Patients With Atopic Dermatitis. <i>J Allergy Clin Immunol.</i> 2019;143:26-35.	<a href="https://www.jacionline.org/article/S0091-6749(18)31664-6/fulltext">https://www.jacionline.org/article/S0091-6749(18)31664-6/fulltext</a>
Paul D, Papier A. Scabies: Refine Your Exam, Avoid These Diagnostic Pitfalls. <i>J Fam Pract.</i> 2020;69:10-17.	<a href="https://www.mdedge.com/familymedicine/article/216301/dermatology/scabies-refine-your-exam-avoid-these-diagnostic-pitfalls">https://www.mdedge.com/familymedicine/article/216301/dermatology/scabies-refine-your-exam-avoid-these-diagnostic-pitfalls</a>

Sanna L, et al. Atopic Disorders and Depression: Findings From a Large, Population-Based Study. <i>J Affect Disord.</i> 2014;155:261-265.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S0165032713008070">https://www.sciencedirect.com/science/article/abs/pii/S0165032713008070</a>
Schaefer P. Acute and Chronic Urticaria: Evaluation and Treatment. <i>Am Fam Physician.</i> 2017;95:717-724.	<a href="https://www.aafp.org/afp/2017/0601/p717.html">https://www.aafp.org/afp/2017/0601/p717.html</a>
Schmitt J, et al. Increased Attention-Deficit/Hyperactivity Symptoms in Atopic Dermatitis Are Associated With History of Antihistamine Use. <i>Allergy.</i> 2018;73:615-626.	<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13326">https://onlinelibrary.wiley.com/doi/abs/10.1111/all.13326</a>
Silverberg NB. A Practical Overview of Pediatric Atopic Dermatitis, Part 3: Differential Diagnosis, Comorbidities, and Measurement of Disease Burden. <i>Cutis.</i> 2016;97:408-412.	<a href="https://pubmed.ncbi.nlm.nih.gov/27416084/">https://pubmed.ncbi.nlm.nih.gov/27416084/</a>
Silverberg JI, et al. Association of Atopic Dermatitis With Allergic, Autoimmune, and Cardiovascular Comorbidities in US Adults. <i>Ann Allergy Asthma Immunol.</i> 2018;121:604-612.e3.	<a href="https://www.annallergy.org/article/S1081-1206(18)30628-8/fulltext">https://www.annallergy.org/article/S1081-1206(18)30628-8/fulltext</a>
Silverberg JI. Comorbidities and the Impact of Atopic Dermatitis. <i>Ann Allergy Asthma Immunol.</i> 2019;123:144-151.	<a href="https://pubmed.ncbi.nlm.nih.gov/31034875/">https://pubmed.ncbi.nlm.nih.gov/31034875/</a>
Silverberg JI. Revolutionizing Atopic Dermatitis. <i>Cutis.</i> 2019;104:142-143.	<a href="https://www.mdedge.com/dermatology/article/207466/atopic-dermatitis/revolutionizing-atopic-dermatitis">https://www.mdedge.com/dermatology/article/207466/atopic-dermatitis/revolutionizing-atopic-dermatitis</a>
Thijs JL, et al. Current and Future Biomarkers in Atopic Dermatitis. <i>Immunol Allergy Clin North Am.</i> 2017;37:51-61.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S0889856116300716">https://www.sciencedirect.com/science/article/abs/pii/S0889856116300716</a>

## Treatment of Atopic Dermatitis

Resource	Address
Bissonnette R, et al. Topical Tofacitinib for Atopic Dermatitis: A Phase IIa Randomized Trial. <i>Br J Dermatol.</i> 2016;175:902-911.	<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14871">https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14871</a>
Blauvelt A, et al. Long-term Management of Moderate-To-Severe Atopic Dermatitis With Dupilumab and Concomitant Topical Corticosteroids (LIBERTY AD CHRONOS): A 1-year, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial. <i>Lancet.</i> 2017;389:2287-2303.	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31191-1/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31191-1/fulltext</a>
Brar KK, et al. Strategies for Successful Management of Severe Atopic Dermatitis. <i>J Allergy Clin Immunol Pract.</i> 2019;7:1-16.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S2213219818306780">https://www.sciencedirect.com/science/article/abs/pii/S2213219818306780</a>

Cotter DG, et al. Emerging Therapies for Atopic Dermatitis: JAK Inhibitors. <i>J Am Acad Dermatol.</i> 2018;78(suppl 1):S53-S62.	<a href="https://www.jaad.org/article/S0190-9622(17)32820-7/fulltext">https://www.jaad.org/article/S0190-9622(17)32820-7/fulltext</a>
Czarnowicki T, et al. Atopic Dermatitis Endotypes and Implications for Targeted Therapeutics. <i>J Allergy Clin Immunol.</i> 2019;143:1-11.	<a href="https://www.jacionline.org/article/S0091-6749(18)31572-0/fulltext">https://www.jacionline.org/article/S0091-6749(18)31572-0/fulltext</a>
Eichenfield LF, et al. Guidelines of Care for the Management of Atopic Dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis. <i>J Am Acad Dermatol.</i> 2014;70:338-351.	<a href="https://www.jaad.org/article/S0190-9622(13)01095-5/fulltext">https://www.jaad.org/article/S0190-9622(13)01095-5/fulltext</a>
Guttman-Yassky E, et al. Baricitinib in Adult Patients With Moderate-To-Severe Atopic Dermatitis: A Phase 2 Parallel, Double-Blinded, Randomized Placebo-Controlled Multiple-Dose Study. <i>J Am Acad Dermatol.</i> 2019;80:913-921.e9.	<a href="https://www.jaad.org/article/S0190-9622(18)30129-4/fulltext">https://www.jaad.org/article/S0190-9622(18)30129-4/fulltext</a>
Jarnagin K, et al. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. <i>J Drugs Dermatol.</i> 2016;15:390-396.	<a href="https://jddonline.com/articles/dermatology/S1545961616P0390X">https://jddonline.com/articles/dermatology/S1545961616P0390X</a>
Li AW, et al. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. <i>JAMA Dermatol.</i> 2017;153:1036-1042.	<a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2643740">https://jamanetwork.com/journals/jamadermatology/article-abstract/2643740</a>
Mobasher P, et al. Oral Small Molecules for the Treatment of Atopic Dermatitis: A Systematic Review. <i>J Dermatolog Treat.</i> 2019;30:550-557.	<a href="https://www.tandfonline.com/doi/full/10.1080/09546634.2018.1544412">https://www.tandfonline.com/doi/full/10.1080/09546634.2018.1544412</a>
Paller AS, et al. Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults. <i>J Am Acad Dermatol.</i> 2016;75:494-503.e6.	<a href="https://www.jaad.org/article/S0190-9622(16)30330-9/fulltext">https://www.jaad.org/article/S0190-9622(16)30330-9/fulltext</a>
Pan Y, et al. A Systematic Review of Ustekinumab in the Treatment of Atopic Dermatitis. <i>J Dermatolog Treat.</i> 2018;29:539-541.	<a href="https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1406894">https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1406894</a>
Ruzicka T, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>N Engl J Med.</i> 2017;376:826-835.	<a href="https://www.nejm.org/doi/10.1056/NEJMoa1606490">https://www.nejm.org/doi/10.1056/NEJMoa1606490</a>
Schlessinger J, et al. Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months With Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). <i>Am J Clin Dermatol.</i> 2020;21:275-284.	<a href="https://link.springer.com/article/10.1007/s40257-020-00510-6">https://link.springer.com/article/10.1007/s40257-020-00510-6</a>

Siegfried EC, et al. Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 Months to <18 Years of Age): Draft Guidance for Industry. <i>Pediatr Dermatol</i> . 2018;35:303-322.	<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13452">https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13452</a>
Simpson EL, et al. A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis. <i>J Invest Dermatol</i> . 2019;139:1063-1072.	<a href="https://www.jidonline.org/article/S0022-202X(18)32905-1/fulltext">https://www.jidonline.org/article/S0022-202X(18)32905-1/fulltext</a>
Simpson EL, et al. Efficacy and Safety of Lebrikizumab (An anti-IL-13 Monoclonal Antibody) in Adults With Moderate-To-Severe Atopic Dermatitis Inadequately Controlled by Topical Corticosteroids: A Randomized, Placebo-Controlled Phase II Trial (TREBLE). <i>J Am Acad Dermatol</i> . 2018;78:863-871.e11.	<a href="https://www.jaad.org/article/S0190-9622(18)30102-6/fulltext">https://www.jaad.org/article/S0190-9622(18)30102-6/fulltext</a>
Simpson EL, et al. Tezepelumab, an Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody, in the Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Phase 2a Clinical Trial. <i>J Am Acad Dermatol</i> . 2019;80:1013-1021.	<a href="https://www.jaad.org/article/S0190-9622(18)33050-0/fulltext">https://www.jaad.org/article/S0190-9622(18)33050-0/fulltext</a>
Thyssen JP, et al. Conjunctivitis in Atopic Dermatitis Patients With and Without Dupilumab Therapy - International Eczema Council Survey and Opinion. <i>J Eur Acad Dermatol Venereol</i> . 2019;33:1224-1231.	<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15608">https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.15608</a>
Treister AD, Lio PA. Long-term Off-Label Dupilumab in Pediatric Atopic Dermatitis: A Case Series. <i>Pediatr Dermatol</i> . 2019;36:85-88.	<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13697">https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.13697</a>
Wang D, Beck LA. Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update. <i>Am J Clin Dermatol</i> . 2016;17:425-443.	<a href="https://link.springer.com/article/10.1007/s40257-016-0205-5">https://link.springer.com/article/10.1007/s40257-016-0205-5</a>

## Atopic Dermatitis Associations and Foundations

Resource	Address
American Academy of Dermatology	<a href="https://www.aad.org/public/diseases/eczema">https://www.aad.org/public/diseases/eczema</a>
American Academy of Pediatrics	<a href="https://www.aap.org/en-us/Pages/Default.aspx">https://www.aap.org/en-us/Pages/Default.aspx</a>
Asthma and Allergy Foundation of America	<a href="http://www.aafa.org/page/eczema.aspx">http://www.aafa.org/page/eczema.aspx</a>
International Eczema Council	<a href="https://www.eczemacouncil.org/">https://www.eczemacouncil.org/</a>
National Eczema Association	<a href="https://nationaleczema.org/">https://nationaleczema.org/</a>
National Eczema Society	<a href="http://www.eczema.org/atopic-eczema">http://www.eczema.org/atopic-eczema</a>